|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
Datamonitor, March 2011, Pages: 107
Introduction
Healthcare expenditure is growing fast in all markets, driven by aging populations, a growing prevalence of chronic diseases, expanding government healthcare coverage, use of expensive drugs. Also, as a result of the economic downturn, healthcare funding is under increased scrutiny by governments in developed markets looking to pay down their debts.
Features and benefits
- An overview of healthcare expenditure in the 12 major markets
- Insight into the major reforms of healthcare systems in the developed and developing markets
- An assessment of the regulatory issues that are affecting global pharma markets.
- Analysis of the key pricing and reimbursement controls that are affecting pharma
Highlights
- As a result, healthcare reforms in EU and Japan focus on containing costs, without impacting quality of service. Ongoing measures include pricing and reimbursement cuts, bolstering generic usage, as well as other cost cutting tools, with the outcome largely negative for branded pharma.
- Although the US health reform law may well result in extended health insurance coverage and increase government involvement in healthcare, costs are expected to escalate. In the short-term though, discounts and rebates implemented as part of the reform are expected to result in drop in US sales.
- Reforms in the emerging markets concentrate on improving the quality and coverage of healthcare, providing opportunities for pharma, particularly for generics manufacturers. Nevertheless, as healthcare access expands and quality improves, funding pressures increase, leading to the introduction of cost-containment.
Your key questions answered
- Evaluate key factors driving healthcare expenditure as well as measures implemented by governments strategies implemented to contain further growth.
- Gain insight into the impact of healthcare reforms in the developed and emerging markets and their impact on pharma.
- Assess pharma’s responses to the increasingly tough regulatory and reimbursement environment.
|
|
|
|
